Nonlinear dynamics of CAR-T cell therapy

被引:0
|
作者
Fassoni, Artur C. [1 ,2 ]
Braga, Denis C. [1 ]
机构
[1] Univ Fed Itajuba, Inst Matemat & Computacao, BR-37500903 Itajuba, Brazil
[2] Tech Univ Dresden, Inst Med Informat & Biometry, Dresden, Germany
关键词
Nonlinear phenomena; Differential equations; Hopf bifurcation; Bogdanov-Takens bifurcation; Mathematical oncology; Immunotherapy; MODELS; PROLIFERATION; BIFURCATIONS; OSCILLATIONS;
D O I
10.1016/j.chaos.2024.115871
中图分类号
O1 [数学];
学科分类号
0701 ; 070101 ;
摘要
Chimeric antigen receptor T-cell (CAR-T) therapy is considered a promising cancer treatment. The dynamic response to this therapy can be broadly divided into a short-term phase, ranging from weeks to months, and a long-term phase, ranging from months to years. While the short-term response, encompassing the multiphasic kinetics of CAR-T cells, is better understood, the mechanisms underlying the outcomes of the long-term response, characterized by sustained remission, relapse, or disease progression, remain less understood due to limited clinical data. Here, we analyze the long-term dynamics of a previously validated mathematical model of CAR-T cell therapy. We perform a comprehensive stability and bifurcation analysis, examining model equilibria and their dynamics over the entire parameter space. Our results show that therapy failure results from a combination of insufficient CAR-T cell proliferation and increased tumor immunosuppression. By combining different techniques of nonlinear dynamics, we identify Hopf and Bogdanov-Takens bifurcations, which allow to elucidate the mechanisms behind oscillatory remissions and transitions to tumor escape. In particular, rapid expansion of CAR-T cells leads to oscillatory tumor control, while increased tumor immunosuppression destabilizes these oscillations, resulting in transient remissions followed by relapse. Our study highlights different mathematical tools to study nonlinear models and provides critical insights into the nonlinear dynamics of CAR-T therapy arising from the complex interplay between CAR-T cells and tumor cells.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Optimizing CAR-T Cell Therapy Against Glioblastoma
    Srivastava, Ambike Aarti
    Schmidts, Andrea
    Choi, Bryan D.
    Maus, Marcela V.
    MOLECULAR THERAPY, 2020, 28 (04) : 503 - 504
  • [32] Secondary Malignancies after CAR-T Cell Therapy
    Rudek, Loreen Sophie
    Alakus, Hakan
    ONKOLOGIE, 2025, 31 (01): : 110 - 111
  • [33] Metabolic engineering for optimized CAR-T cell therapy
    Sarah J. McPhedran
    Gillian A. Carleton
    Julian J. Lum
    Nature Metabolism, 2024, 6 : 396 - 408
  • [34] China enters CAR-T cell therapy era
    Cao, Xin
    Li, Wei
    Yu, Yiyi
    Liu, Tianshu
    Zhou, Yuhong
    INNOVATION, 2022, 3 (01):
  • [35] CAR-T Cell Therapy: the Efficacy and Toxicity Balance
    Chohan, Karan L.
    Siegler, Elizabeth L.
    Kenderian, Saad S.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2023, 18 (02) : 9 - 18
  • [36] CAR-T cells, the first pharmaceutical cell therapy
    Laurence, Arian
    TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (05)
  • [37] Current Status and Prospects of CAR-T Cell Therapy
    Xiao, Meng
    Shi, Yuan-yuan
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2023, 50 (05) : 953 - 961
  • [38] Glycoengineering a more effective CAR-T cell therapy
    Lau, Lee Seng
    Ortega, Liettel
    Posey, Avery
    Stowell, Sean R.
    Dimitroff, Charles
    GLYCOBIOLOGY, 2022, 32 (11) : 1047 - 1048
  • [39] Metabolic engineering for optimized CAR-T cell therapy
    Mcphedran, Sarah J.
    Carleton, Gillian A.
    Lum, Julian J.
    NATURE METABOLISM, 2024, 6 (03) : 396 - 408
  • [40] CAR-T Cell Therapy for Classical Hodgkin Lymphoma
    Katsin, Mikalai
    Dormeshkin, Dmitri
    Meleshko, Alexander
    Migas, Alexandr
    Dubovik, Simon
    Konoplya, Natalya
    HEMASPHERE, 2023, 7 (12): : E971